Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy
- PMID: 27775756
- DOI: 10.1001/jama.2016.16437
Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy
Erratum in
-
Error in Text.JAMA. 2017 Apr 11;317(14):1482. doi: 10.1001/jama.2017.2823. JAMA. 2017. PMID: 28399234 No abstract available.
Comment in
-
FDA Approval of Eteplirsen for Muscular Dystrophy.JAMA. 2017 Apr 11;317(14):1480-1481. doi: 10.1001/jama.2017.2597. JAMA. 2017. PMID: 28399244 No abstract available.
-
FDA Approval of Eteplirsen for Muscular Dystrophy.JAMA. 2017 Apr 11;317(14):1480. doi: 10.1001/jama.2017.2601. JAMA. 2017. PMID: 28399245 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources